

GLAXOSMITHKLINE PLC

Form 6-K

July 14, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 14 July 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms E Walmsley
 - b) Position/status Chief Executive Officer
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882
 - b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017, on shares held through the Company's Share Reward Plan.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.2549	13
n/a (single transaction)	
 - d) Aggregated information
Aggregated volume Price
 - e) Date of the transaction 2017-07-13
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr R G Connor
 - b) Position/status President, Global Manufacturing & Supply
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted
 Ordinary shares of 25 pence
 each ('Ordinary Shares')
- a) Description of the financial instrument
 ISIN: GB0009252882
 Acquisition of Ordinary
 Shares following the
 re-investment of dividends
 paid to shareholders on 13
 July 2017, on shares held
 through the Company's Share
 Reward Plan.
- b) Nature of the transaction
- c) Price(s) and volume(s)
 Price(s) Volume(s)
 £16.2549 52
 n/a (single transaction)

Aggregated information

- d) Aggregated volume Price

- e) Date of the transaction 2017-07-13
 f) Place of the transaction London Stock Exchange
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr S Dingemans
 b) Position/status Chief Financial Officer
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

- Ordinary shares of 25 pence
 each ('Ordinary Shares')
- a) Description of the financial instrument
 ISIN: GB0009252882
 Acquisition of Ordinary
 Shares following the
 re-investment of dividends
 paid to shareholders on 13
 July 2017, on shares held
- b) Nature of the transaction

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

through the Company's Share
Reward Plan.

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£16.2549	17
Aggregated information	n/a (single transaction)	

d) Aggregated volume Price

e) Date of the transaction 2017-07-13

f) Place of the transaction London Stock Exchange
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr N Hirons
b) Position/status SVP, Global Ethics &
Compliance

c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence
each ('Ordinary Shares')

b) Nature of the transaction ISIN: GB0009252882
Acquisition of Ordinary
Shares following the
re-investment of dividends
paid to shareholders on 13
July 2017, on shares held
through the Company's Share
Reward Plan.

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£16.2549	7
	n/a (single transaction)	

Aggregated information

d) Aggregated volume Price

e) Date of the transaction 2017-07-13

f) Place of the transaction London Stock Exchange
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name Mr S A Hussain
 b) Position/status President, Global Pharmaceuticals
 c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
- b) Nature of the transaction ISIN: GB0009252882
 Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017, on shares held through the Company's Share Reward Plan.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|--------------------------|-----------|
| £16.2549 | 12 |
| n/a (single transaction) | |
- d) Aggregated information
 Aggregated volume Price
- e) Date of the transaction 2017-07-13
 f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr D S Redfern
 b) Position/status Chief Strategy Officer
 c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882
 Acquisition of Ordinary
 Shares following the
 re-investment of dividends
 paid to shareholders on 13
 July 2017, on shares held
 through the Company's Share
 Reward Plan.

b) Nature of the transaction

c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.2549	60
n/a (single transaction)	

Aggregated information

d) Aggregated volume Price

e) Date of the transaction 2017-07-13

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms C Thomas

b) Position/status SVP, Human Resources

c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882
 Acquisition of Ordinary
 Shares following the
 re-investment of dividends
 paid to shareholders on 13
 July 2017, on shares held
 through the Company's Share
 Reward Plan.

b) Nature of the transaction

c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.2549	60
n/a (single transaction)	

d) Aggregated information

Aggregated volume Price

- e) Date of the transaction 2017-07-13
- f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr P C Thomson
- b) Position/status President, Global Affairs
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
- ISIN: GB0009252882
- Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017, on shares held through the Company's Share Reward Plan.
- b) Nature of the transaction
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|--------------------------|-----------|
| £16.2549 | 33 |
| n/a (single transaction) | |
- d) Aggregated information
- Aggregated volume Price
- e) Date of the transaction 2017-07-13
- f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Dr P J T Vallance
- b) Position/status President, R&D
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017, on shares held through the Company's Share Reward Plan.
 - b) Nature of the transaction
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.2549	36
n/a (single transaction)	
 - d) Aggregated information

Aggregated volume Price
 - e) Date of the transaction 2017-07-13
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mrs V A Whyte
 - b) Position/status Company Secretary
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882
 - b) Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends

paid to shareholders on 13
July 2017, on shares held
through the Company's Share
Reward Plan.

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£16.2549	42
	n/a (single transaction)	

d) Aggregated information
Aggregated volume Price

e) Date of the transaction	2017-07-13
f) Place of the transaction	London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: July 14, 2017

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc